相关实验视频

Updated: Jun 27, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K

塞尔珀卡提尼布在RET突变型红细胞瘤中的临床活性

Barbara Deschler-Baier1, Bhavana Konda2, Erminia Massarelli3

  • 1Comprehensive Cancer Center, University Hospital Würzburg, 97080 Würzburg, Germany.

The Journal of clinical endocrinology and metabolism
|April 25, 2024
PubMed
概括

塞尔珀卡提尼布有效治疗有偶发性或多发性内分泌新陈代谢2型 (MEN2) 综合征的患者的RET突变性染细胞瘤. 这种RET激酶抑制剂在这些罕见的瘤中显示出显著的抗瘤活性和持久的反应.

关键词:
在RET的基础上,RET是RET.叶染色细胞瘤 ( pheochromocytoma) 是一种致血性细胞瘤.塞尔珀卡提尼布 (selpercatinib) 是一种可以

更多相关视频

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.1K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K

相关概念视频

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
159